Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLK1 | P53350 | 16/20 | 0.51 |
| ▸ | PLK2 | Q9NYY3 | 15/20 | 0.51 |
| ▸ | PLK3 | Q9H4B4 | 13/20 | 0.51 |
| ▸ | BRD4 | O60885 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | PIP4K2A | P48426 | 1/20 | 0.34 |
| ▸ | PIP4K2B | P78356 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL382821 | 1.00 | PLK1 (0.51) | PLK1PLK2PLK3BRD4MAPK1 | |
| SCHEMBL92593 | 1.00 | PLK1 (0.51) | PLK1PLK2PLK3BRD4MAPK1 | |
| SCHEMBL30523195 | 1.00 | PLK1 (0.51) | PLK1PLK2PLK3BRD4MAPK1 | |
| SCHEMBL1288242 | 0.98 | PLK1 (0.49) | PLK1PLK2PLK3BRD4MAPK1 | |
| SCHEMBL1288243 | 0.98 | PLK1 (0.49) | PLK1PLK2PLK3BRD4MAPK1 | |
| SCHEMBL5936768 | 0.95 | PLK1 (0.46) | PLK1PLK2PLK3BRD4MAPK1 | |
| SCHEMBL31098106 | 0.92 | PLK1 (0.44) | PLK1PLK2PLK3BRD4MAPK1 | |
| SCHEMBL5936900 | 0.90 | PLK1 (0.43) | PLK1PLK2PLK3BRD4MAPK1 | |
| SCHEMBL14952207 | 0.88 | PLK1 (0.43) | PLK1PLK2PLK3BRD4KDM4E | |
| SCHEMBL23849199 | 0.87 | PIP4K2A (0.41) | PLK1PLK2PLK3BRD4KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115947728-B | Sulfonyl-containing dihydropteridinone derivatives and their use | 沈阳药科大学 | 2024-01-09 | — | — | CN | disclosed |
| CN-115947728-A | Dihydro pteridinone derivative containing sulfonyl and application thereof | 沈阳药科大学 | 2023-04-11 | — | — | CN | disclosed |
| EP-2481739-B1 | DIHYDROPTERIDINONE DERIVATIVES, PREPARATION PROCESS AND PHARMACEUTICAL USE THEREOF | JIANGSU HANSOH PHARMACEUTICAL CO LTD (CN) | 2016-12-14 | — | — | EP | disclosed |
| EP-2481739-B1 | DIHYDROPTERIDINONE DERIVATIVES, PREPARATION PROCESS AND PHARMACEUTICAL USE THEREOF | JIANGSU HANSOH PHARMACEUTICAL CO LTD (CN) | 2016-12-14 | — | — | EP | disclosed |
| US-8691822-B2 | Dihydropteridinone derivatives, preparation process and pharmaceutical use thereof | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2014-04-08 | — | — | US | disclosed |
| US-8691822-B2 | Dihydropteridinone derivatives, preparation process and pharmaceutical use thereof | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2014-04-08 | — | — | US | disclosed |
| EP-2481739-A1 | DIHYDROPTERIDINONE DERIVATIVES, PREPARATION PROCESS AND PHARMACEUTICAL USE THEREOF | Jiangsu Hengrui Medicine Co., Ltd. (CN) | 2012-08-01 | — | — | EP | disclosed |
| EP-2481739-A1 | DIHYDROPTERIDINONE DERIVATIVES, PREPARATION PROCESS AND PHARMACEUTICAL USE THEREOF | Jiangsu Hengrui Medicine Co., Ltd. (CN) | 2012-08-01 | — | — | EP | disclosed |
| US-20120184543-A1 | DIHYDROPTERIDINONE DERIVATIVES, PREPARATION PROCESS AND PHARMACEUTICAL USE THEREOF | SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. (CN) | 2012-07-19 | — | — | US | disclosed |
| US-20120184543-A1 | DIHYDROPTERIDINONE DERIVATIVES, PREPARATION PROCESS AND PHARMACEUTICAL USE THEREOF | SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. (CN) | 2012-07-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120184543-A1 | DIHYDROPTERIDINONE DERIVATIVES, PREPARATION PROCESS AND PHARMACEUTICAL USE THEREOF | PLK2, PLK3, DMPK | PLK1 201/4885PLK2 1/4885PLK3 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.